Investor Presentaiton

17 Alvotech is pursuing a strategically selected biosimilar portfolio of attractive molecules Biosimilar Candidate Reference Biologic Therapeutic Area Early Phase Pre-clinical Clinical Trial(s) Filing Approval Approved by: AVTO2 high-concentration adalimumab AVTO4 ustekinumab AVTO3 denosumab AVTO6 aflibercept AVT23* omalizumab AVTO5 golimumab AVT16 vedolizumab EYLEAⓇ XOLAIR SIMPONIⓇ/ Immunology SIMPONI ARIA® ENTYVIOⓇ HUMIRA® Immunology EC, Health Canada MHRA, TGA STELARAⓇ Immunology PROLIAⓇ/XGEVAⓇ Immunology/ Oncology Filed in Major Markets PK and Patient Study Initiated Patient Study Ophthalmology Respiratory Initiated PK Study Completed PK and Patient Study Initiated Immunology AVT33 KEYTRUDAⓇ® Oncology pembrolizumab AVT19 Undisclosed Undisclosed AVT21 Undisclosed Undisclosed AVT41 Undisclosed Undisclosed alvotech Launch Launched in: Canada Europe (16) HUMIRA is a registered trademark of AbbVie Inc. STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Janssen Biotech, Inc. XOLAIR is a registered trademark of Novartis AG PROLIA AND XGEVA are registered trademarks of Amgen, Inc. EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc. ENTYVIO is a registered trademark of Millennium Pharmaceuticals, Inc. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp. © ALVOTECH. ALL RIGHTS RESERVED

View entire presentation